Exploring GoodRx Holdings, Inc. (GDRX) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind GoodRx Holdings, Inc. (GDRX), and what their investment strategies might be? As of April 16, 2025, the stock price stands at $4.45 per share, a decrease from $6.50 on April 17, 2024. With institutional investors holding a significant 142,627,810 shares, understanding their moves is crucial. Are they accumulating, holding, or reducing their positions, and what does it signal for the future of GDRX? Let's dive into the investor profile of GoodRx, exploring who's buying, who's selling, and the potential reasons driving their decisions.

GoodRx Holdings, Inc. (GDRX) Who Invests in GoodRx Holdings, Inc. (GDRX) and Why?

Understanding the investor profile of GoodRx Holdings, Inc. (GDRX) involves examining the diverse range of entities and individuals who hold stakes in the company, as well as their motivations and strategies. This includes a breakdown of investor types, what attracts them to GoodRx Holdings, Inc. (GDRX), and the typical investment strategies they employ.

Key Investor Types:

The investor base of GoodRx Holdings, Inc. (GDRX) is composed of a mix of retail investors, institutional investors, and hedge funds.

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Their investment decisions are often influenced by factors such as personal financial goals, risk tolerance, and information gathered from various sources, including financial news, company reports, and investment advice.
• Institutional Investors: This category includes entities such as mutual funds, pension funds, insurance companies, and investment firms that manage large sums of money on behalf of others. Institutional investors typically have sophisticated research capabilities and make investment decisions based on in-depth analysis of financial data, industry trends, and macroeconomic factors.
• Hedge Funds: These are investment partnerships that use a variety of strategies to generate returns for their investors. Hedge funds often employ more aggressive tactics, such as short selling, leverage, and derivative instruments, to capitalize on market opportunities.

Investment Motivations:

Several factors attract investors to GoodRx Holdings, Inc. (GDRX), with growth prospects being a primary driver.

• Growth Prospects: Investors are drawn to GoodRx Holdings, Inc. (GDRX)'s potential for growth in the healthcare technology sector. The company's innovative platform, which provides consumers with access to affordable prescription medications, positions it to capitalize on the increasing demand for cost-effective healthcare solutions.
• Market Position: GoodRx Holdings, Inc. (GDRX)'s established market position and brand recognition are also attractive to investors. As a leading provider of prescription drug price comparisons and discounts, the company has built a strong reputation among consumers and healthcare professionals.

Investment Strategies:

Investors in GoodRx Holdings, Inc. (GDRX) employ various strategies, depending on their investment objectives and risk tolerance.

• Long-Term Holding: Some investors adopt a long-term holding strategy, buying shares of GoodRx Holdings, Inc. (GDRX) with the intention of holding them for an extended period. These investors are typically focused on the company's long-term growth potential and are willing to ride out short-term market fluctuations.
• Short-Term Trading: Other investors engage in short-term trading, seeking to profit from short-term price movements in GoodRx Holdings, Inc. (GDRX)'s stock. These traders may use technical analysis and other tools to identify trading opportunities and execute trades quickly.
• Value Investing: Value investors look for companies that they believe are undervalued by the market. They may be attracted to GoodRx Holdings, Inc. (GDRX) if they believe that the company's stock price does not fully reflect its intrinsic value.

Analyzing the composition of GoodRx Holdings, Inc. (GDRX)'s investor base, along with their motivations and strategies, provides valuable insights into the market's perception of the company and its future prospects. Understanding these dynamics can help current and prospective investors make informed decisions about their investments in GoodRx Holdings, Inc. (GDRX).

Here is a table illustrating potential investment strategies and motivations:

For further insights into the financial health of GoodRx Holdings, Inc. (GDRX), consider exploring: Breaking Down GoodRx Holdings, Inc. (GDRX) Financial Health: Key Insights for Investors

GoodRx Holdings, Inc. (GDRX) Institutional Ownership and Major Shareholders of GoodRx Holdings, Inc. (GDRX)

Understanding the institutional ownership of GoodRx Holdings, Inc. (GDRX) provides valuable insights into the company's investor base and market sentiment. Institutional investors, which include mutual funds, hedge funds, pension funds, and other large financial institutions, often hold significant stakes in publicly traded companies. Their investment decisions can have a notable impact on a company's stock price and overall strategy.

As of December 31, 2024, the top institutional holders of GoodRx Holdings, Inc. (GDRX) are:

• Vanguard Group Inc: As of March 31, 2025, Vanguard Group Inc. holds 10,888,495 shares.
• BlackRock Fund Advisors: As of March 31, 2025, BlackRock Fund Advisors holds 7,319,264 shares.
• RA Capital Management, L.P.: As of December 31, 2024, RA Capital Management, L.P. holds 6,486,784 shares.
• FMR LLC: As of March 31, 2025, FMR LLC holds 4,929,736 shares.
• ARK Investment Management LLC: As of March 31, 2025, ARK Investment Management LLC holds 4,147,745 shares.

These major institutional investors wield considerable influence due to the size of their holdings. Their investment strategies and decisions are closely watched by other investors, as they can signal confidence or concerns about the company's prospects.

Changes in institutional ownership can provide insights into the evolving sentiment surrounding GoodRx Holdings, Inc. (GDRX). Increases in institutional holdings may indicate growing confidence in the company's future performance, while decreases may suggest concerns about potential challenges or a shift in investment strategy.

Recent changes in ownership include:

• Vanguard Group Inc: Increased holdings by 3.1% in Q4 2024.
• BlackRock Fund Advisors: Decreased holdings by 3.8% in Q4 2024.
• RA Capital Management, L.P.: Increased holdings by 6.2% in Q4 2024.
• FMR LLC: Increased holdings by 1.5% in Q4 2024.
• ARK Investment Management LLC: Decreased holdings by 2.7% in Q4 2024.

These changes reflect ongoing evaluations of GoodRx Holdings, Inc. (GDRX) by major institutional investors, influenced by factors such as the company's financial performance, market trends, and competitive landscape.

Institutional investors play a crucial role in shaping the stock price and strategy of GoodRx Holdings, Inc. (GDRX). Their trading activity can drive significant price movements, and their engagement with company management can influence strategic decisions.

The presence of large institutional investors can provide stability to the stock price, as they tend to have a longer-term investment horizon compared to individual investors. Their active participation in shareholder meetings and proxy votes can also influence corporate governance and strategic direction.

For additional insights into GoodRx Holdings, Inc. (GDRX), you might find this resource helpful: Mission Statement, Vision, & Core Values of GoodRx Holdings, Inc. (GDRX).

The following table summarizes the ownership data for the top institutional investors in GoodRx Holdings, Inc. (GDRX) as of December 31, 2024:

Understanding these ownership dynamics is essential for investors seeking to gain a comprehensive view of GoodRx Holdings, Inc. (GDRX) and its position in the market.

GoodRx Holdings, Inc. (GDRX) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of GoodRx Holdings, Inc. (GDRX) provides valuable insights into the company's stability, growth potential, and strategic direction. Examining the key investors, their influence, and recent moves can help stakeholders assess the overall sentiment and potential impact on the company's performance.

As of April 2025, GoodRx Holdings, Inc. has 288 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 142,627,810 shares.

Here are some of the notable investors in GoodRx Holdings, Inc. (GDRX):

• Francisco Partners Management, LP: Holds a significant position in GoodRx.
• Vanguard Group Inc: A major institutional investor with a substantial number of shares.
• Rubric Capital Management LP: Another key institutional investor with a notable stake.
• Lakewood Capital Management, LP: Maintains a considerable position in the company.
• Ameriprise Financial Inc: Holds a significant number of shares.
• Silver Lake Group, L.L.C.: Another key institutional investor.
• Abdiel Capital Management LLC: Notably, Abdiel Capital Management LLC is the largest individual shareholder, owning 23.80 million shares, representing 6.20% of the company. These shares are valued at $98.04 million.

These major shareholders can include individual investors, mutual funds, hedge funds, or institutions.

The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

Institutional ownership in GoodRx Holdings, Inc. stands at 128.28%. The total shares outstanding are 107 million, with a total value of holdings amounting to $609 million.

Here's a glimpse of the top institutional holders and their positions as of December 31, 2024:

Recent moves by these investors, such as buying or selling large stakes, can significantly influence stock movements and company decisions.

Recent news indicates the following insider trading activity:

• Number of Shares Bought (3 Months): 20,028,741
• Number of Shares Sold (3 Months): 20,202,897
• Total Shares Traded (3 Months): 40,231,638
• Net Activity (3 Months): (174,156)
• Number of Shares Bought (12 Months): 40,509,783
• Number of Shares Sold (12 Months): 40,483,519
• Total Shares Traded (12 Months): 80,993,302
• Net Activity (12 Months): 26,264

The Fund Sentiment Score is an important metric to consider. The scoring model uses a combination of the total increase in disclosed owners, the changes in portfolio allocations in those owners, and other metrics. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average.

For more insights into GoodRx Holdings, Inc.'s financial health, you can explore this resource: Breaking Down GoodRx Holdings, Inc. (GDRX) Financial Health: Key Insights for Investors

GoodRx Holdings, Inc. (GDRX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for assessing the potential of GoodRx Holdings, Inc. (GDRX). This analysis includes major shareholders, recent market behavior, and analyst perspectives to provide a comprehensive view.

Major Shareholders

GoodRx Holdings, Inc. has a mix of institutional and individual investors. Key institutional holders include:

• Francisco Partners Management, LP: Holding 70.08 million shares as of December 31, 2024, representing 65.65% of the outstanding shares.
• Vanguard Group Inc: Holding 8.37 million shares as of December 31, 2024, accounting for 7.84% of shares.
• Rubric Capital Management LP: Holding 5.8 million shares as of December 31, 2024, with a 5.44% stake.
• Lakewood Capital Management, LP: Holding 4.89 million shares as of December 31, 2024, representing 4.58% of the shares.
• Ameriprise Financial, Inc: Holding 4.81 million shares as of December 31, 2024, holding 4.50% of the company's shares.
• Silver Lake Group, LLC: Holding 3.53 million shares as of December 31, 2024, accounting for 3.31% of shares.
• Petrus Trust Company, LTA: Holding 2.95 million shares as of December 31, 2024, holding 2.76% of the company's shares.
• Renaissance Technologies, LLC: Holding 2.88 million shares as of December 31, 2024, holding 2.70% of the company's shares.
• Rip Road Capital Partners LP: Holding 2.41 million shares as of December 31, 2024, holding 2.26% of the company's shares.

These major holders can significantly influence the company's direction and stability.

Institutional Ownership

Institutional investors hold a substantial portion of GoodRx shares. As of April 16, 2025, 288 institutional owners and shareholders have filed 13D/G or 13F forms with the SEC, holding a total of 142,627,810 shares. Institutional ownership accounts for approximately 63.35% of the shares outstanding.

Market Capitalization Trends

GoodRx Holdings has experienced market capitalization fluctuations:

In 2024, GoodRx's market capitalization decreased from $2.73 billion in January to $1.78 billion by December.

Recent Market Reactions

Recent events have triggered varied market reactions:

• New E-commerce Platform Launch: In April 2025, the launch of a new e-commerce platform saw shares decline by 6.5%, closing at $4.01, amid a global stock market downturn.
• Earnings Report: GoodRx's Q4 2024 earnings showed an EPS of $0.09, slightly below the forecasted $0.10. Nonetheless, pre-market trading saw shares rise by 1.23%.
• Analyst Ratings: Following positive analyst ratings, the stock hit a 52-week low at $4.09 in early April 2025.

Overall, the stock has shown volatility, influenced by both company-specific news and broader market trends.

Analyst Perspectives

Analysts have mixed views on GoodRx, but there is an overall positive outlook:

• Raymond James: Reaffirmed a Strong Buy rating with a $9.00 price target, citing solid quarterly results and attractive valuation.
• Citi: Raised the price target to $6.75 from $6.25, maintaining a Buy rating, highlighting a 1% year-over-year revenue increase and a 466 basis points expansion in adjusted EBITDA margins.
• Mizuho Securities: Noted GoodRx's growing market share and the new CEO's identification of a stronger value proposition for retail pharmacies.
• Zacks Investment Research: GoodRx's launch of its new e-commerce platform could drive long-term stock growth by enhancing user convenience, deepening partnerships with major retail pharmacies, and expanding its role in the digital healthcare space.

Analysts' consensus points to potential growth, driven by strategic initiatives and improving financial metrics.

Financial Performance

GoodRx's financial performance in 2024 shows both growth and areas of concern:

• Revenue: Increased by 6% to $792.3 million for the full year 2024.
• Net Income: Turned positive at $16.4 million compared to a net loss of $8.9 million in 2023.
• Adjusted EBITDA: Increased by 20% year-over-year to $260.2 million.
• Prescription Transactions Revenue: Increased by 5% year-over-year to $577.5 million.
• Subscription Revenue: Decreased by 8% year-over-year to $86.5 million, due to the sunset of the Kroger Savings Club partnership.
• Pharma Manufacturer Solutions Revenue: Increased by 26% year-over-year to $107.2 million.

Investor Sentiment

Overall investor sentiment appears cautiously optimistic, with analysts noting the company's potential for growth and strategic improvements. However, market reactions to recent news indicate some uncertainty. Indian investors' search interest for GoodRx stock has decreased by 33% in the last 30 days, reflecting a downward trend in search activity.

For further insights into GoodRx's financial standing, consider exploring: Breaking Down GoodRx Holdings, Inc. (GDRX) Financial Health: Key Insights for Investors.